CN
CN
Carna Biosciences Announces License Agreement with BioNova Pharmaceuticals to Develop and Commercialize AS-1763 in Greater China
March 16, 2020

KOBE March 16, 2020 - Carna Biosciences Inc. (JASDAQ: 4572) today announced that it has entered into a license agreement with BioNova Pharmaceuticals Limited (BioNova) to develop and commercialize AS-1763, a novel next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor for the Greater China territory.